Lilly's Foundayo (Orforglipron) Weight-Loss Pill Approved by FDA

Dans le même genre

• Santé23/09/2026@HealthDesk

  Lilly Submits Retatrutide to the FDA for Approval

  Eli Lilly·…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States

  Commence le 31/03/2027ESTIMÉ3 mois de retardCONFIANCE 77 %dans 189 joursLilly "plans to subsequently submit retatrutide in Q1 2027 for U.S. approval" - no day is given, so the pin takes the last day of the first quarter of 2027.^[1]

  Lilly plans to file its Biologics License Application for retatrutide, the triple-hormone obesity shot that cut weight by up to 28.3% in Phase 3, with the FDA in the first quarter of 2027, once its manufacturing data package is complete.

  0.77

  00
• Santé23/09/2026@HealthDesk

  Lilly lance la construction d'une usine Foundayo de 6,5 milliards de dollars à Generation Park, Houston

  Eli Lilly·…North Lake Houston Parkway, Generation Park, Harris County, Texas, 77050, United States

  Commence le 21/09/2026CONFIRMÉCONFIANCE 84 %avant-hierLe communiqué de Lilly porte la mention "HOUSTON^[4], 21 septembre 2026" et indique que Lilly "a posé la première pierre aujourd'hui à Houston, Texas^[6]" ; Community Impact^[2] rapporte que la cérémonie s'est tenue le 21 septembre.

  Une usine de 236 acres qui produira le principe actif de la pilule amaigrissante Foundayo de Lilly, avec plus de 600 emplois permanents et environ 4 000 emplois de chantier. Lilly la prévoit opérationnelle d'ici 2030.

  $6.5B

  0.74

  00
• Santé23/09/2026@HealthDesk

  Retatrutide Delivers 28.3% Weight Loss in Lilly's TRIUMPH-1 Phase 3 Trial

  Eli Lilly·…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States

  Commence le 21/05/2026CONFIRMÉCONFIANCE 87 %il y a 125 joursLilly's release is datelined "INDIANAPOLIS, May 21, 2026" and says the company "today announced positive topline results from TRIUMPH-1".^[1]

  People on the top 12 mg dose of Lilly's triple-hormone shot retatrutide lost an average of 28.3% of their body weight (70.3 lbs) over 80 weeks, and 30.3% by two years in the extension - weight loss at the level of bariatric surgery.

  0.71

  00
• Santé23/09/2026@HealthDesk

  Lilly Presents eloraTZP Phase 2 Results at EASD 2026 in Milan

  Allianz MiCo, Via Demetrio Stratos, Bolla, Milan, Lombardy 20149, ItalyEli Lilly·…

  

  Commence le 30/09/2026 14:30PROGRAMMÉCONFIANCE 86 %dans 7 joursLilly's release lists "EloraTZP symposium | Wednesday, September 30, 2026 | 4:30 to 5:30 p.m. CEST", and the EASD^[2] 2026 Final Programme puts the session at 16:30 - 17:30 on Wednesday 30 September in Budapest Hall.

  First Phase 2 results for eloraTZP - Lilly's once-weekly amylin drug eloralintide combined with tirzepatide (Mounjaro, Zepbound) - in adults with obesity or overweight and type 2 diabetes, unveiled at an EASD symposium on amylin in Milan.

  0.69

  00
• Santé23/09/2026@HealthDesk

  FDA Authorizes Abbott's Libre Duo Glucose-Ketone Sensor

  Abbott Laboratories·…1360 South Loop Road, Alameda, Alameda County, California, 94502, United States

  Commence le 25/08/2026CONFIRMÉCONFIANCE 87 %il y a 29 joursThe release is datelined "ABBOTT PARK, Ill., Aug. 25, 2026" and says Abbott "today announced U.S. Food and Drug Administration (FDA^[2][3]) authorization of its Libre Duo 10 Day system"; the FDA's De Novo record gives the same decision date, 08/25/2026.

  The FDA authorized Abbott's Libre Duo 10 Day, the first wearable to continuously track both glucose and ketones, which alerts people with diabetes aged 2 and older to rising ketones before diabetic ketoacidosis.

  0.69

  00
• Santé20/09/2026@HealthDesk

  Enicepatide's Phase 3 Trial in Obesity or Overweight Reads Out

  RocheBasel, Canton of Basel-Stadt, Switzerland

  Commence le 24/07/2028ESTIMÉCONFIANCE 50 %dans 1,8 anClinicalTrials.gov^[1] lists 2028-07-24 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

  Roche's phase 3 trial of Enicepatide in obesity or overweight reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,000 participants. The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity.

  0.69

  00
• Santé23/09/2026@HealthDesk

  La FDA approuve Inluriyo de Lilly associé à Verzenio contre le cancer du sein muté ESR1

  Eli Lilly·…Bowditch Road, Federal Research Center, Hillandale, Montgomery County, Maryland, 20993, United States

  Commence le 18/09/2026CONFIRMÉCONFIANCE 85 %il y a 5 joursLe communiqué de Lilly porte la mention "INDIANAPOLIS, 18 septembre 2026" et indique qu'il "a annoncé aujourd'hui que la Food and Drug Administration (FDA^[4]) américaine a accordé une approbation complète" ; l'avis de la FDA elle-même fixe la date d'approbation au 18 septembre 2026.

  Une association entièrement orale qui a doublé la survie médiane sans progression, de 5,5 à 11,1 mois, chez les patientes mutées ESR1 dans l'essai EMBER-3. C'est la deuxième approbation de la FDA pour Inluriyo en moins d'un an.

  0.69

  00
• Santé23/09/2026@HealthDesk

  Lilly Agrees to Acquire Centessa for Up to $7.8 Billion

  Eli Lilly·…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States

  Commence le 31/03/2026CONFIRMÉCONFIANCE 87 %il y a 176 joursThe joint release is datelined "INDIANAPOLIS and BOSTON and LONDON, March 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Centessa".^[1]

  Lilly agrees to buy Centessa Pharmaceuticals, maker of the orexin agonist cleminorexton for narcolepsy, for $38 a share in cash (about $6.3 billion) plus a CVR worth up to $1.5 billion more; the deal closed on 24 June 2026.

  $7.8B

  0.68

  00
• Santé20/09/2026@HealthDesk

  Elecoglipron's Phase 3 Trial in Type 2 Diabetes Mellitus Reads Out

  AstraZeneca·…Cambridge, United Kingdom

  Commence le 05/07/2028ESTIMÉCONFIANCE 50 %dans 1,8 anClinicalTrials.gov^[1] lists 2028-07-05 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

  AstraZeneca's phase 3 trial of Elecoglipron in type 2 diabetes mellitus reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,000 participants. The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.

  0.67

  00
• Santé20/09/2026@HealthDesk

  AZD6234's Phase 3 Trial in Obesity or Overweight Reads Out

  AstraZeneca·…Cambridge, United Kingdom

  Commence le 11/08/2028ESTIMÉCONFIANCE 50 %dans 1,9 anClinicalTrials.gov^[1] lists 2028-08-11 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

  AstraZeneca's phase 3 trial of AZD6234 in obesity or overweight reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,500 participants. The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

  0.67

  00
• Santé23/09/2026@HealthDesk

  FDA Approves Icotyde, the First Oral IL-23 Receptor Pill for Psoriasis

  Johnson & Johnson·…Spring House, Lower Gwynedd Township, Montgomery County, Pennsylvania, 19477, United States

  Commence le 17/03/2026 20:12CONFIRMÉCONFIANCE 88 %il y a 190 joursThe FDA's^[4] approval letter for NDA 220149 says the application "is approved, effective on the date of this letter" and was electronically signed "03/17/2026 04:12:23 PM" (Eastern, 20:12 UTC); J&J announced it the next morning: "SPRING HOUSE, Pa. (March 18, 2026) - ... announced today that the U.S. Food and Drug Administration (FDA) has approved ICOTYDE".

  The FDA approved Johnson & Johnson's Icotyde (icotrokinra), a once-daily pill and the first targeted oral peptide to block the IL-23 receptor, for moderate-to-severe plaque psoriasis in adults and children 12 and older weighing at least 40 kg.

  0.66

  00
• Santé20/09/2026@HealthDesk

  Elecoglipron's Phase 3 Trial in Weight Management Reads Out

  AstraZeneca·…Cambridge, United Kingdom

  Commence le 31/07/2028ESTIMÉCONFIANCE 50 %dans 1,9 anClinicalTrials.gov^[1] lists 2028-07-31 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

  AstraZeneca's phase 3 trial of Elecoglipron in weight management reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 4,500 participants. This master study protocol, Study D7260C00015, covers 2 independent, pivotal studies, Study 1 and Study 2. Each study is a global, randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adults living with obesity or overweight with at least one weight-related comorbidity, and without T2DM (Study 1) or with T2DM (Study 2).

  0.66

  00